Potent Preclinical Efficacy of DuoHexaBody-CD37 in B-Cell Malignancies

被引：6
|
作者：
van der Horst, Hilma J. [1 ]
Oostindie, Simone C. [2 ,3 ]
Cillessen, Saskia. A. G. M. [4 ]
Gelderloos, Anne T. [1 ]
Overdijk, Marije B. [2 ]
Nijhof, Inger. S. [1 ]
Zweegman, Sonja [1 ]
Chamuleau, Martine E. D. [1 ]
Breij, Esther C. W. [2 ]
Mutis, Tuna [1 ]
机构：
[1] Vrije Univ Amsterdam Med Ctr, Amsterdam UMC, Canc Ctr Amsterdam, Dept Hematol, Amsterdam, Netherlands
[2] Genmab, Utrecht, Netherlands
[3] Leiden Univ, Med Ctr, Dept Immunohematol & Blood Transfus, Leiden, Netherlands
[4] Amsterdam UMC, Dept Clin Pathol, Amsterdam, Netherlands
来源：
HEMASPHERE | 2021年 / 5卷 / 01期
关键词：
COMPLEMENT; RITUXIMAB; CD37; ANTIBODY; THERAPY;
D O I：
10.1097/HS9.0000000000000504
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页数：4
相关论文
共 50 条
  • [1] DuoHexaBody-CD37®, a novel biparatopic CD37 antibody with enhanced Fc-mediated hexamerization as a potential therapy for B-cell malignancies
    Simone C. Oostindie
    Hilma J. van der Horst
    Laurens P. Kil
    Kristin Strumane
    Marije B. Overdijk
    Edward N. van den Brink
    Jeroen H. N. van den Brakel
    Hendrik J. Rademaker
    Berris van Kessel
    Juliette van den Noort
    Martine E. D. Chamuleau
    Tuna Mutis
    Margaret A. Lindorfer
    Ronald P. Taylor
    Janine Schuurman
    Paul W. H. I. Parren
    Frank J. Beurskens
    Esther C. W. Breij
    Blood Cancer Journal, 10
  • [2] DuoHexaBody-CD37(R), a novel biparatopic CD37 antibody with enhanced Fc-mediated hexamerization as a potential therapy for B-cell malignancies
    Oostindie, Simone C.
    van der Horst, Hilma J.
    Kil, Laurens P.
    Strumane, Kristin
    Overdijk, Marije B.
    van den Brink, Edward N.
    van den Brakel, Jeroen H. N.
    Rademaker, Hendrik J.
    van Kessel, Berris
    van den Noort, Juliette
    Chamuleau, Martine E. D.
    Mutis, Tuna
    Lindorfer, Margaret A.
    Taylor, Ronald P.
    Schuurman, Janine
    Parren, Paul W. H. I.
    Beurskens, Frank J.
    Breij, Esther C. W.
    BLOOD CANCER JOURNAL, 2020, 10 (03)
  • [3] Duohexabody-CD37, a Novel Bispecific Antibody with a Hexamerization-Enhancing Mutation Targeting CD37, Demonstrates Superior Complement-Dependent Cytotoxicity in Preclinical B-Cell Malignancy Models
    Oostindie, Simone C.
    Van der Horst, Hilma J.
    Overdijk, Marije B.
    Strumane, Kristin
    Verploegen, Sandra
    Lindorfer, Margaret A.
    Cook, Erica M.
    Chamuleau, Martine E. D.
    Mutis, Tuna
    Schuurman, Janine
    Sasser, A. Kate
    Taylor, Ronald P.
    Parren, Paul W. H. I.
    Beurskens, Frank J.
    Breij, Esther C. W.
    BLOOD, 2018, 132
  • [4] Targeting CD37 in B-Cell Malignancies Using the Novel Therapeutic Duohexabody-CD37 Results in Efficient Killing of Tumor B-Cells Ex Vivo Via Complement-Dependent Cytotoxicity, Even in Relapsed and/or Refractory Patient Samples
    Van der Horst, Hilma J.
    Oostindie, Simone C.
    Cillessen, Saskia A. G. M.
    Gelderloos, Anne T.
    Overdijk, Marije B.
    Chamuleau, Martine E. D.
    Breij, Esther C. W.
    Mutis, Tuna
    BLOOD, 2018, 132
  • [5] Anti-CD37 targeted immunotherapy of B-Cell malignancies
    Payandeh, Zahra
    Noori, Effat
    Khalesi, Bahman
    Mard-Soltani, Maysam
    Abdolalizadeh, Jalal
    Khalili, Saeed
    BIOTECHNOLOGY LETTERS, 2018, 40 (11-12) : 1459 - 1466
  • [6] Anti-CD37 targeted immunotherapy of B-Cell malignancies
    Zahra Payandeh
    Effat Noori
    Bahman Khalesi
    Maysam Mard-Soltani
    Jalal Abdolalizadeh
    Saeed Khalili
    Biotechnology Letters, 2018, 40 : 1459 - 1466
  • [7] Potent B-Cell Depletion by IMGN529, a CD37-Targeting Antibody-Maytansinoid Conjugate for the Treatment of B-Cell Malignancies
    Deckert, Jutta
    Chicklas, Sharon
    Yi, Yong
    Li, Min
    Pinkas, Jan
    Chittenden, Thomas
    Lutz, Robert J.
    Park, Peter U.
    BLOOD, 2011, 118 (21) : 1591 - 1592
  • [8] Multifaceted mechanism of action of DuoHexaBody-CD37 involves both complement- and Fc gamma receptor-mediated cytotoxicity in pre-clinical B-cell lymphoma models
    Kil, Laurens P.
    Oostindie, Simone C.
    Strumane, Kristin
    van der Horst, Hilma J.
    van Kessel, Berris
    Overdijk, Marije B.
    Lingnau, Andreas
    Brandhorst, Marcel
    van den Brakel, Jeroen
    Lindorfer, Margaret A.
    Taylor, Ronald P.
    Chamuleau, Martine E.
    Mutis, Tuna
    Sasser, A. Kate
    Schuurman, Janine
    Parren, Paul W.
    Beurskens, Frank J.
    Breij, Esther C.
    CANCER RESEARCH, 2020, 80 (16)
  • [9] Preclinical evaluation of anti-CD37 antibody-targeted amanitin conjugates (ATAC) in B-cell malignancies.
    Voss, Stephanie
    Palfi, Aniko
    Mueller, Christoph
    Pahl, Andreas
    Hechler, Torsten
    Kulke, Michael
    CANCER RESEARCH, 2021, 81 (13)
  • [10] A nonfucosylated human antibody to CD19 with potent B-cell depletive activity for therapy of B-cell malignancies
    Cardarelli, Pina M.
    Rao-Naik, Chetana
    Chen, Sharline
    Huang, Haichun
    Pham, Amie
    Moldovan-Loomis, Maria-Cristina
    Pan, Chin
    Preston, Ben
    Passmore, David
    Liu, Jie
    Kuhne, Michelle R.
    Witte, Alison
    Blanset, Diann
    King, David J.
    CANCER IMMUNOLOGY IMMUNOTHERAPY, 2010, 59 (02) : 257 - 265
12345